EU approves Trimbow for asthma – Chiesi
The European Commission has approved a marketing authorisation for triple combination Trimbow (beclometasone + formoterol + glycopyrronium) from Chiesi, for patiemts with asthma therapy.
The marketing authorisation approves Trimbow for use as a maintenance treatment for adult asthma patients, whose condition is not adequately controlled with a combination of long-acting beta2-agonist (LABA) and medium dose of inhaled corticosteroid (ICS). Patients must have also experienced one or more asthma exacerbations in the previous year.
This triple asthma therapy has been shown to reduce exacerbations and improve lung function in patients with uncontrolled asthma, compared to ICS/LABA. The EC’s approval are based on efficacy and safety data from four clinical studies, involving almost 3,000 patients.